Red Light truffles compatible with manufacturing plans

Executive Summary

• Red Light Holland Corp. received initial third-party testing results from Irvine Labs Inc. confirming the psilocybin quantity and process compatibility of its naturally occurring psilocybin products for potential medical-grade manufacturing.
• The testing validates that Red Light Holland's naturally derived psilocybin truffles are compatible with proprietary dehydration and packaging processes being developed by Irvine Labs to extend shelf life while maintaining product integrity.
• Preparations are underway for the next scheduled import of psilocybin under Irvine Labs' existing 2025 DEA quota allocation, supporting ongoing collaborative R&D for standardized products for therapeutic markets and clinical trials.

Key Details

• Testing Partner: Irvine Labs Inc., an FDA-compliant and DEA-registered facility in California.
• Product Tested: Naturally derived psilocybin truffles from Red Light Holland’s Netherlands facility.
• Test Results: Confirmed psilocybin quantity and compatibility with manufacturing processes for potential medical-grade applications.
• Process Development: Irvine Labs is advancing proprietary dehydration and packaging processes designed to extend shelf life and maintain product integrity.
• Regulatory/Logistics: Preparations are underway for the next scheduled import under Irvine Labs' existing 2025 DEA quota allocation.
• Strategic Goal: Collaborative efforts aim to create a commercialized, standardized psilocybin product for legal distribution in emerging markets and utilization in government-funded pilot programs and clinical trials in the United States.

Notable Quotes

• Todd Shapiro, CEO and Director, Red Light Holland: "We are pleased to receive these initial testing results confirming that our naturally derived psilocybin products are compatible with the manufacturing processes being developed. This validation represents progress in our partnership with Irvine Labs and moves us forward in developing standardized psilocybin products for emerging therapeutic markets."
• Shaun Land, President, Irvine Labs: "The initial testing results validate our process development approach with Red Light Holland's psilocybin materials. We are now focused on optimizing our proprietary preservation processes and preparing for expanded operations. These results confirm our ability to work with Red Light Holland's materials in developing products for potential medical-grade applications, which supports our goal of advancing government-funded pilot programs and clinical trials."